What makes a drug fall into the “specialty” drug category is a combination of several factors. First, they tend to be very expensive. This is because they were recently approved, meaning they are under an active patent with no generic or biosimilar version available.
A new study out by Prescryptive Health, a healthcare technology company, found that while 95% of people know they can comparison shop for drugs, very few do.
Mark Cuban’s eponymous online pharmacy was an interesting new twist in the U.S. drug pricing dilemma this past January. The Cost Plus Drugs Company sells
Recently, RazorMetrics was brought in to be evaluated on our hard numbers: time to ROI, actual savings, and real prescriber response stats. When we pulled
The Inflation Reduction Bill passed the House last November (2021) then it hit the Senate and stalled. After a long pause and some wheeling and dealing, it squeaked by in the Senate on August 7th. Then, it flew back through the House on Friday the 12th and now, will be signed by the President in the coming days. Now that it has passed the legislature, here is what you need to know about how the Inflation Reduction Bill will impact healthcare:
In a recent guest essay in the New York Times entitled, “What’s Wrong With Health Insurance? Deductibles Are Ridiculous, for Starters” by Dr. Aaron E. Carroll, what I found the most interesting was the comment section.
Fighting cancer is hard enough, but paying for the treatments can be overwhelming. Cancer drugs are treated differently than other types of drugs for several
The cost of a new drug treatment has soared into the stratosphere, dramatically impacting consumers. These findings came out of a recent study by researchers
A recent story at CBSNews highlighted a disturbing new trend – massive layoffs among top tech companies. Whether this is tied to the predicted recession,
The pharmacy benefits landscape may be shifting with the new Federal Trade Commission appointee Alvaro Bedoya. He should be the tie-breaker in the 2-2 gridlock that has plagued the commission. One of the stymied issues has been whether the FTC should move forward in its investigation into the cost of insulin.
And, we are waiting…
Contact us, and we will be more than happy to answer all of your questions.
